Other OTC - Other OTC Delayed Price. Currency in USD


Allée de la Recherche, 60
Brussels 1070
32 2 559 99 99

Full Time Employees7,500

Key Executives

Mr. Jean-Christophe TellierChief Exec. Officer and Exec. Director3.77MN/A59
Mr. Detlef ThielgenChief Financial Officer and Exec. VPN/AN/A58
Ms. Anna S. RichoExec. VP and Gen. CounselN/AN/A58
Dr. Bharat TewarieChief Marketing Officer and Exec. VPN/AN/A57
Prof. Iris L??w-FriedrichChief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VPN/AN/A58
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy. Its product pipeline includes UCB0942 for highly drug resistant epilepsy; dapirolizumab pegol for systemic lupus erythematosus; bimekizumab for various indications; bimekizumab, add-on to Cimzia for rheumatoid arthritis; seletalisib for Sj??gren's syndrome; UCB7665 for immune thrombocytopenia; UCB1332 for Parkinson's disease; UCB4144/VR942 for asthma; UCB6673 for immunological diseases; UCB3491 for epilepsy; and UCB7858 for auto-inflammatory diseases. UCB SA was founded in 1928 and is headquartered in Brussels, Belgium.

Corporate Governance

UCB SA’s ISS Governance QualityScore as of January 1, 2018 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.